SCHEMBL6715255

SCHEMBL6715255

CC(=O)OCCN1CCCc2cc[c]cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 14/20 0.39
CHRM4 P08173 14/20 0.39
CHRM1 P11229 14/20 0.39
CHRM3 P20309 14/20 0.39
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38
SLC18A3 Q16572 1/20 0.36
NOTUM Q6P988 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
CASP1 P29466 1/20 0.36
HTT P42858 1/20 0.36
CASP7 P55210 1/20 0.36
SMAD3 P84022 1/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713240 0.90 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3MEN1
SCHEMBL11326320 0.82 ALDH1A1 (0.58) CHRM2CHRM4CHRM1CHRM3MEN1
SCHEMBL6716466 0.80 REN (0.48) CHRM2CHRM4CHRM1CHRM3NOTUM
SCHEMBL6713047 0.80 CYP3A4 (0.48) CHRM2CHRM4CHRM1CHRM3MEN1
SCHEMBL6717277 0.79 CHRM2 (0.56) CHRM2CHRM4CHRM1CHRM3MEN1
SCHEMBL6233572 0.79 ALDH1A1 (0.38) CHRM2CHRM4CHRM1CHRM3ALDH1A1
SCHEMBL1451125 0.78 MEN1 (0.42) CHRM2CHRM4CHRM1CHRM3MEN1
SCHEMBL6714618 0.78 REN (0.47) CHRM2CHRM4CHRM1CHRM3MEN1
SCHEMBL6232687 0.78 NOTUM (0.43) CHRM2CHRM4CHRM1CHRM3MEN1
SCHEMBL1452216 0.78 ALDH1A1 (0.48) MEN1ALDH1A1KMT2ANOTUMTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040214832-A1 Piperazine derivative renin inhibitors WARNER-LAMBERT COMPANY LLC 2004-10-28 US claimed
US-20040204455-A1 Piperidine derivative rennin inhibitors WARNER-LAMBERT COMPANY LLC 2004-10-14 US claimed
US-20040214832-A1 Piperazine derivative renin inhibitors WARNER-LAMBERT COMPANY LLC 2004-10-28 US disclosed
WO-2004089915-A1 PIPERAZINE DERIVATIVE RENIN INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-10-21 WO disclosed
US-20040204455-A1 Piperidine derivative rennin inhibitors WARNER-LAMBERT COMPANY LLC 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204455-A1 Piperidine derivative rennin inhibitors REN, ACE, HPN CHRM2 4480/4885CHRM4 4577/4885CHRM1 4505/4885
US-20040214832-A1 Piperazine derivative renin inhibitors REN, ACE, AGTR2 CHRM2 4588/4885CHRM4 4619/4885CHRM1 4672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.